drugset / Trial / NCT02601716

PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults

NCT02601716

RandomizedParallel-groupOpen-labelPrevention

Summary

This is an open-label evaluation of the safety, tolerability, immunogenicity and efficacy of PfSPZ Vaccine administered by direct venous inoculation (DVI) in healthy, malaria-naïve adult subjects.

Timeline

Start
2016-01
Primary completion
2017-09
Completion
2017-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject PfSPZ Vaccine Vaccine 225000 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 450000 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 900000 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 1.8e+06 unknown Intravenous
Subject PfSPZ Vaccine Vaccine 2.7e+06 unknown Intravenous

Indications